Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Gastroenterology and Hepatology 3, 220–228 (1 April 2006) | doi:10.1038/ncpgasthep0447
Drug Insight: antagonists of tumor-necrosis factor-|[alpha]| in the treatment of inflammatory bowel disease
&
Abstract
In the past decade, advances in the understanding of the pathogenesis of inflammatory bowel disease have permitted the development of agents directed against rational therapeutic targets. In particular, various antagonists of tumor-necrosis factor-α have been developed. These include infliximab, adalimumab, certolizumab (CDP870), CDP571, etanercept, and onercept. Clinical trials of these agents have demonstrated varying degrees of clinical efficacy. The use of these agents can be limited by infection, immunogenicity, acute infusion reactions, delayed hypersensitivity reactions, and autoimmune phenomena. This review provides insights into the use of antagonists of tumor-necrosis factor-α for the treatment of inflammatory bowel disease.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
